What are the indications and dosing recommendations for eltrombopag?

Eltrombopag: Indications and Dosing

Eltrombopag is a thrombopoietin receptor agonist used to increase platelet production in three main conditions: immune thrombocytopenia (ITP), severe aplastic anemia, and thrombocytopenia associated with chronic hepatitis C. 1

Mechanism of Action

Eltrombopag binds to the transmembrane domain of the TPO receptor (cMpl), triggering signaling cascades that stimulate megakaryocyte proliferation and differentiation, ultimately increasing platelet production. Platelet counts typically peak approximately two weeks after starting treatment and return to baseline within two weeks of discontinuation. 1

FDA-Approved Indications

1. Immune Thrombocytopenia (ITP)

• Adults and pediatric patients ≥6 years with persistent or chronic ITP who have insufficient response to corticosteroids, immunoglobulins, or splenectomy 1
• The 2019 ASH guidelines conditionally recommend TPO receptor agonists (including eltrombopag) for adults with ITP lasting ≥3 months who are corticosteroid-dependent or have no response to corticosteroids 2

2. Severe Aplastic Anemia

• Refractory severe aplastic anemia in patients who have had insufficient response to immunosuppressive therapy 1

3. Chronic Hepatitis C-Associated Thrombocytopenia

• To allow initiation and maintenance of interferon-based therapy 1

Dosing Recommendations

Immune Thrombocytopenia (ITP)

Standard Adult Dosing:

• Initial dose: 50 mg once daily 1
• East/Southeast Asian ancestry: Start at 25 mg once daily (due to 50-55% higher drug concentrations) 1
• Hepatic impairment (Child-Pugh A, B, or C): Start at 25 mg once daily 1

Pediatric Dosing (≥6 years):

• Initial dose: 50 mg once daily 1
• East/Southeast Asian ancestry: Start at 25 mg once daily 1
• Hepatic impairment: Start at 25 mg once daily 1

Dose Titration:

• Adjust dose in 25 mg increments every 2 weeks to achieve and maintain platelet count ≥50 × 10⁹/L as needed to reduce bleeding risk 1
• Maximum dose: 75 mg once daily 1
• Monitor platelet counts weekly until stable, then monthly 1

Severe Aplastic Anemia

Adult Dosing:

• Initial dose: 50 mg once daily 1
• East/Southeast Asian ancestry: Start at 25 mg once daily 1
• Hepatic impairment: Start at 25 mg once daily 1
• Adjust in 50 mg increments every 2 weeks as necessary
• Maximum dose: 150 mg once daily 1

Chronic Hepatitis C-Associated Thrombocytopenia

Adult Dosing:

• Initial dose: 25 mg once daily 1
• Adjust in 25 mg increments every 2 weeks to target platelet count needed to initiate antiviral therapy
• Maximum dose: 100 mg once daily 1
• No dose adjustment needed for hepatic impairment in HCV patients 1

Critical Administration Requirements

Food and Drug Interactions:

• Take on an empty stomach (1 hour before or 2 hours after food) 1
• High-fat meals decrease absorption by approximately 36% 1
• Separate from polyvalent cations (calcium, aluminum, magnesium, iron, zinc) by at least 4 hours, as these chelate eltrombopag and limit absorption 1
• Meals with ≤50 mg calcium do not significantly impact absorption 1

Key Safety Considerations

Hepatotoxicity: Monitor liver function tests before starting, every 2 weeks during dose adjustment, then monthly. Baseline ALT/AST >5× ULN is a contraindication in aplastic anemia patients 1

Thrombotic Risk: Thrombosis occurred in approximately 2.5% of ITP patients on TPO receptor agonists 2. Monitor platelet counts closely to avoid excessive increases (target <400 × 10⁹/L for most indications) 1

Cataracts: Perform baseline and periodic ophthalmologic examinations 1

Clinical Context from Guidelines

The 2019 ASH guidelines note that patient preference drives the choice between eltrombopag and romiplostim, as there is no significant difference in efficacy between the two agents 2. Eltrombopag offers oral daily administration versus weekly subcutaneous injection with romiplostim, but requires dietary restrictions. For adults with ITP <12 months' duration, the guidelines conditionally favor TPO receptor agonists over rituximab due to greater durability of response with ongoing use 2.

Common pitfall: Patients often struggle with the dietary restrictions required for eltrombopag (avoiding calcium-rich foods and supplements within 4 hours of dosing), which can affect adherence and efficacy 2. Consider this when choosing between eltrombopag and romiplostim.